171.24 USD
-5.06
2.87%
At close Apr 1, 4:00 PM EDT
After hours
171.24
+0.00
0.00%
1 day
-2.87%
5 days
-5.01%
1 month
-7.36%
3 months
-12.24%
6 months
-25.99%
Year to date
-12.24%
1 year
-31.19%
5 years
71.17%
10 years
152.31%
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 9 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

1.21% less ownership

Funds ownership: 85.87% [Q3] → 84.66% (-1.21%) [Q4]

6% less funds holding

Funds holding: 1,043 [Q3] → 982 (-61) [Q4]

18% less capital invested

Capital invested by funds: $37B [Q3] → $30.2B (-$6.77B) [Q4]

24% less repeat investments, than reductions

Existing positions increased: 320 | Existing positions reduced: 423

25% less first-time investments, than exits

New positions opened: 128 | Existing positions closed: 170

29% less funds holding in top 10

Funds holding in top 10: 14 [Q3] → 10 (-4) [Q4]

36% less call options, than puts

Call options by funds: $165M | Put options by funds: $260M

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$210
23%
upside
Avg. target
$243
42%
upside
High target
$270
58%
upside

9 analyst ratings

positive
78%
neutral
22%
negative
0%
Citigroup
Patrick Donnelly
23% 1-year accuracy
7 / 31 met price target
23%upside
$210
Neutral
Maintained
4 Mar 2025
JP Morgan
Anne Samuel
51% 1-year accuracy
18 / 35 met price target
35%upside
$232
Overweight
Maintained
18 Feb 2025
Morgan Stanley
Tejas Savant
21% 1-year accuracy
4 / 19 met price target
46%upside
$250
Overweight
Maintained
11 Feb 2025
RBC Capital
Sean Dodge
31% 1-year accuracy
11 / 35 met price target
58%upside
$270
Outperform
Reiterated
10 Feb 2025
Truist Securities
Jailendra Singh
37% 1-year accuracy
13 / 35 met price target
54%upside
$263
Buy
Reiterated
10 Feb 2025

Financial journalist opinion

Based on 4 articles about IQV published over the past 30 days

Positive
Zacks Investment Research
6 days ago
Here's Why Investors Must Hold IQV Stock in Their Portfolios Now
The IQV stock is benefiting from partner retention, acquisition and investment in AI-led innovation.
Here's Why Investors Must Hold IQV Stock in Their Portfolios Now
Neutral
Business Wire
3 weeks ago
IQVIA recognized as a leader in IDC MarketScape's 2024 assessment for decentralized clinical trial technologies and consulting services
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions and clinical research services to the healthcare and life sciences industries, has been named to the “Leaders” category of the IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Technology Solutions and Consulting Services 2024 Vendor Assessment. IDC, a global provider of market intelligence, says in its report: “Consider IQVIA when s.
IQVIA recognized as a leader in IDC MarketScape's 2024 assessment for decentralized clinical trial technologies and consulting services
Positive
Zacks Investment Research
3 weeks ago
IQVIA Gains From Diversified Client Base Despite Low Liquidity Woes
The IQV stock benefits from its healthcare-centric IT infrastructure across the globe and a treasure trove of data distinguishing it from its competitors.
IQVIA Gains From Diversified Client Base Despite Low Liquidity Woes
Neutral
Business Wire
4 weeks ago
IQVIA Laboratories launches Site Lab Navigator with breakthrough e-Requisition innovation to transform clinical trials
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Laboratories, a leading global drug discovery and development laboratory services organization, announces the launch of Site Lab Navigator, an advanced suite of solutions that automates and streamlines lab workflows for clinical trial sponsors and investigator sites. At the core of Site Lab Navigator is a new, innovative e-Requisition solution, which allows investigator sites to submit requisitions and manage lab specimens electronically, eli.
IQVIA Laboratories launches Site Lab Navigator with breakthrough e-Requisition innovation to transform clinical trials
Neutral
Business Wire
1 month ago
Global Healthy Living Foundation and IQVIA Institute Report Millions of Adult Vaccines Likely Missed When States Restrict Pharmacist Participation
UPPER NYACK, N.Y.--(BUSINESS WIRE)--When pharmacists can't give adult vaccinations, millions of people go without them.
Global Healthy Living Foundation and IQVIA Institute Report Millions of Adult Vaccines Likely Missed When States Restrict Pharmacist Participation
Positive
Zacks Investment Research
1 month ago
IQVIA Holdings (IQV) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
IQVIA Holdings (IQV) is a Top-Ranked Value Stock: Should You Buy?
Neutral
Business Wire
1 month ago
IQVIA AI Assistant wins 2024 PM360 Innovation Award for Artificial Intelligence
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences and healthcare industries, today announced that IQVIA AI Assistant has been awarded a 2024 PM360 Innovation Award in the Artificial Intelligence category. Launched in September 2024, IQVIA AI Assistant revolutionizes insight generation by providing rapid, relevant and precise answers to complex business questio.
IQVIA AI Assistant wins 2024 PM360 Innovation Award for Artificial Intelligence
Neutral
Business Wire
1 month ago
IQVIA CFO Ron Bruehlman to Speak at the TD Cowen Annual Health Care Conference on March 4, 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the TD Cowen Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a lead.
IQVIA CFO Ron Bruehlman to Speak at the TD Cowen Annual Health Care Conference on March 4, 2025
Neutral
Business Wire
1 month ago
IQVIA Releases 2024 Sustainability Report
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has published its 2024 Sustainability Report. The report details IQVIA's sustainability achievements consistent with its mission to accelerate innovation for a healthier world. “IQVIA combines technology and scientific expertise with our unique information assets and Healthcare-gr.
IQVIA Releases 2024 Sustainability Report
Neutral
Zacks Investment Research
1 month ago
NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight
ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management.
NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight
Charts implemented using Lightweight Charts™